Renaissance Technologies’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-444,800
| Closed | -$667K | – | 4417 |
|
|
2023
Q1 | $667K | Sell |
444,800
-248,486
| -36% | -$335K | ﹤0.01% | 2717 |
|
|
2022
Q4 | $692K | Sell |
693,286
-13,614
| -2% | -$18.4K | ﹤0.01% | 2748 |
|
|
2022
Q3 | $1.27M | Sell |
706,900
-44,400
| -6% | -$129K | ﹤0.01% | 2352 |
|
|
2022
Q2 | $2.18M | Sell |
751,300
-691,300
| -48% | -$1.71M | ﹤0.01% | 2118 |
|
|
2022
Q1 | $3.98M | Buy |
1,442,600
+550,700
| +62% | +$1.73M | ﹤0.01% | 1753 |
|
|
2021
Q4 | $4.16M | Buy |
891,900
+698,100
| +360% | +$4.36M | 0.01% | 1647 |
|
|
2021
Q3 | $1.65M | Buy |
193,800
+32,400
| +20% | +$458K | ﹤0.01% | 2237 |
|
|
2021
Q2 | $2.65M | Buy |
161,400
+12,900
| +9% | +$261K | ﹤0.01% | 2061 |
|
|
2021
Q1 | $3.28M | Buy |
+148,500
| New | +$4.05M | ﹤0.01% | 1916 |
|
|
2020
Q4 | – | Sell |
-67,700
| Closed | -$1.38M | – | 3817 |
|
|
2020
Q3 | $1.38M | Buy |
67,700
+33,600
| +99% | +$590K | ﹤0.01% | 2329 |
|
|
2020
Q2 | $524K | Sell |
34,100
-17,200
| -34% | -$198K | ﹤0.01% | 2857 |
|
|
2020
Q1 | $397K | Buy |
+51,300
| New | +$628K | ﹤0.01% | 2870 |
|
Renaissance Technologies's TCRR Position: Q2 2023 in Review
Renaissance Technologies sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 444,800 shares — an estimated $667K sold.
Renaissance Technologies first reported a position in TCRR in Q1 2020 and held it in 12 quarters. The position peaked at $4.16M in Q4 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Renaissance Technologies reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Renaissance Technologies sold 444,800 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $667K.
- Renaissance Technologies first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 12 quarters.
- Renaissance Technologies's TCR2 Therapeutics Inc. Common Stock position peaked at $4.16M in Q4 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.